Clinical Value of Circulating MiRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 29

PMID 36982210

Authors

Jakub Wnuk

Joanna Katarzyna Strzelczyk

Iwona Gisterek

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) is considered to be the seventh most common cause of cancer-related deaths. The number of deaths caused by PC is estimated to increase in the future. An early diagnosis of PC is crucial for improving treatment outcomes. The most common histopathological subtype of PC is pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs)-which are endogenous non-coding RNAs involved in the posttranscriptional regulation of multiple gene expression-constitute useful diagnostic and prognostic biomarkers in various neoplasms, including PDAC. Circulating miRNAs detected in a patient's serum or plasma are drawing more and more attention. Hence, this review aims at evaluating the clinical value of circulating miRNA in the screening, diagnosis, prognosis and monitoring of pancreatic ductal adenocarcinoma therapy.

Citing Articles

Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma.

Wnuk J, Hudy D, Strzelczyk J, Michalecki L, Dybek K, Gisterek-Grocholska I Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852142 PMC: 11763715. DOI: 10.3390/cimb47010027.

MicroRNA Gets a Mighty Award.

Li Y, Chen S, Rao H, Cui S, Chen G Adv Sci (Weinh). 2025; 12(7):e2414625.

PMID: 39836690 PMC: 11831481. DOI: 10.1002/advs.202414625.

Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.

Diagnostic Utility of MicroRNAs in Pancreatic Cancers.

Jelski W, Mroczko J, Okrasinska S, Mroczko B Cancers (Basel). 2024; 16(22).

PMID: 39594763 PMC: 11593317. DOI: 10.3390/cancers16223809.

Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pancreatic Ductal Adenocarcinoma.

Popov A, Hrudka J, Szabo A, Oliverius M, Subrt Z, Vranova J Biomedicines. 2024; 12(5).

PMID: 38790924 PMC: 11117927. DOI: 10.3390/biomedicines12050962.

References

Hindson C, Chevillet J, Briggs H, Gallichotte E, Ruf I, Hindson B . Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013; 10(10):1003-5. PMC: 4118677. DOI: 10.1038/nmeth.2633. View

Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I . Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol. 2014; 46(2):539-47. PMC: 4277249. DOI: 10.3892/ijo.2014.2743. View

Lu H, Lu S, Yang D, Zhang L, Ye J, Li M . MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Biosci Rep. 2019; 39(5). PMC: 6504660. DOI: 10.1042/BSR20181374. View

Aita A, Millino C, Sperti C, Pacchioni B, Plebani M, De Pitta C . Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study. Biomedicines. 2021; 9(7). PMC: 8301411. DOI: 10.3390/biomedicines9070845. View

Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y . Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene. 2018; 673:181-193. DOI: 10.1016/j.gene.2018.06.037. View

Hamam R, Hamam D, Alsaleh K, Kassem M, Zaher W, Alfayez M . Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017; 8(9):e3045. PMC: 5636984. DOI: 10.1038/cddis.2017.440. View

Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

Guraya S . Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. Int J Surg. 2018; 60:41-47. DOI: 10.1016/j.ijsu.2018.10.030. View

Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T . CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008; 9(2):132-8. DOI: 10.1016/S1470-2045(08)70001-9. View

10.

Mazza T, Gioffreda D, Fontana A, Biagini T, Carella M, Palumbo O . Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer. Front Oncol. 2020; 10:44. PMC: 7010806. DOI: 10.3389/fonc.2020.00044. View

11.

Kong X, Du Y, Wang G, Gao J, Gong Y, Li L . Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2010; 56(2):602-9. DOI: 10.1007/s10620-010-1285-3. View

12.

Franklin O, Jonsson P, Billing O, Lundberg E, Ohlund D, Nystrom H . Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. Ann Surg. 2017; 267(4):775-781. PMC: 5865497. DOI: 10.1097/SLA.0000000000002124. View

13.

Ganepola G, Rutledge J, Suman P, Yiengpruksawan A, Chang D . Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014; 6(1):22-33. PMC: 3936193. DOI: 10.4251/wjgo.v6.i1.22. View

14.

Jiang D, Yuan X, Ni J, Shen L, Cai M, Xu L . Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study. Can J Gastroenterol Hepatol. 2021; 2021:8882129. PMC: 8213505. DOI: 10.1155/2021/8882129. View

15.

Takizawa S, Matsuzaki J, Ochiya T . Circulating microRNAs: Challenges with their use as liquid biopsy biomarkers. Cancer Biomark. 2022; 35(1):1-9. PMC: 9661319. DOI: 10.3233/CBM-210223. View

16.

Xu J, Cao Z, Liu W, You L, Zhou L, Wang C . Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Ann Surg. 2015; 263(6):1173-9. DOI: 10.1097/SLA.0000000000001345. View

17.

Yuan W, Tang W, Xie Y, Wang S, Chen Y, Qi J . New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer. Oncotarget. 2016; 7(48):80033-80045. PMC: 5346769. DOI: 10.18632/oncotarget.12406. View

18.

Zou X, Wei J, Huang Z, Zhou X, Lu Z, Zhu W . Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Cancer Med. 2019; 8(6):2810-2822. PMC: 6558458. DOI: 10.1002/cam4.2145. View

19.

Peng C, Wang J, Gao W, Huang L, Liu Y, Li X . Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer. Int J Med Sci. 2021; 18(3):660-671. PMC: 7797557. DOI: 10.7150/ijms.52706. View

20.

Vietsch E, Peran I, Suker M, van den Bosch T, van der Sijde F, Kros J . Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Appl Sci (Basel). 2021; 9(22). PMC: 8415800. DOI: 10.3390/app9224784. View